Eurofins: 2026Q2 Earnings

Latest Earnings Summary: H1 2026 Investing.com

Eurofins Scientific reports financial results on a half-year basis, with H1 2026 (ended June 30, 2026) representing the latest official reporting period:

Investing.com

Total Revenues: €3,701 million, an increase of 2.5% on a reported basis and 2.7% on an organic basis compared to €3,612 million in H1 2025. Top-line growth absorbed a 2.9% foreign exchange headwind caused by a stronger euro. Investing.com+ 1
Adjusted EBITDA: €877 million (+8.3% YoY), achieving an Adjusted EBITDA margin of 23.7% (+130 bps YoY). Investing.com+ 1
Reported EBITDA: €862 million (+11.4% YoY), with reported EBITDA margin expanding 190 bps to 23.3%. Investing.com+ 1
Separately Disclosed Items (SDI): Decreased 58.0% to €15 million (0.4% of revenue), benefiting from improved profitability in early-stage laboratories and €19 million in one-time legal settlement gains. Finnhub+ 1
Diluted/Basic EPS: Basic EPS rose 29.4% YoY to €1.55 (vs. €1.20 in H1 2025), driven by operational leverage, SDI reductions, and share repurchases. Investing.com
Cash Flow & Capital Structure: Free Cash Flow to the Firm (FCFF) jumped 46.1% to €403 million, bringing cash conversion to 47% (vs. 36% in H1 2025). Net debt stood at €3,854 million with financial leverage held flat at 2.2x EBITDA, well within the 1.5x–2.5x target range. Business Wire

Segment and Regional Revenue Breakdown

Eurofins classifies its activities across four main business segments and three primary geographical regions.

Business Line Breakdown (H1 2026 Total: €3,701m) Investing.com

Life (Food & Feed, Environment Testing): ~€1,547 million (41.8% of revenue). Covers analytical testing for food authenticity, contaminants, microbiological safety, water, air, and soil quality. Posted 4.8% organic growth, driven by environmental testing volume recoveries in Europe and sustained regulatory testing demand in North America. Investing.com
BioPharma Services: ~€1,039 million (28.1% of revenue). Encompasses product testing, discovery pharmacology, genomic services, and contract development and manufacturing (CDMO). Revenue was roughly flat (-0.1% organic growth) due to subdued biotech funding and expiring CDMO contracts in Europe, partially counterbalanced by solid North American product testing and onshoring trends. Bnains.org+ 2
Diagnostic Services & Products: ~€760 million (20.5% of revenue). Comprises human clinical diagnostics, specialized pathology, prenatal screening, and in-vitro diagnostics. Grew 0.6% organically, with volume gains partially tempered by contract rationalization in Europe following regulatory fee schedule pressures. Investing.com
Consumer & Technology Products Testing (CPT): ~€356 million (9.6% of revenue). Provides electrical/wireless device certifications, material analyses, and consumer goods safety checks. Delivered 7.4% organic growth, propelled by advanced semiconductor testing demand and aerospace/defense contract expansions in North America. Investing.com

Geographic Revenue Breakdown

Europe: €1,961 million (53.0% of revenue). Reported revenue grew 5.7% (2.0% organically), bolstered by M&A integration (e.g., Synlab Spanish assets) and cost discipline, pushing regional EBITDA margins up 210 bps to 18.6%. Finnhub+ 1
North America: €1,334 million (36.0% of revenue). Organic growth was 2.0%, though reported revenue slipped 2.7% due to currency drag. Regional reported EBITDA margin expanded 230 bps to 30.8%, helped by pricing power and legal settlements. Finnhub+ 1
Rest of the World (APAC, LATAM, MEA): €406 million (11.0% of revenue). Delivered the fastest organic growth at 9.1%, driven by food testing market share gains and expanding biopharma testing platforms in Southeast Asia and India. Bnains.org+ 1

Key Changes This Period, Near-Term Focus, and Outlook

Key Changes in H1 2026: Business Wire
- Operational Efficiency & SDI Run-Down: The drag from non-mature laboratory start-ups narrowed sharply, with EBITDA losses on start-up units dropping to €8 million. Mature scope operations (€3,462 million revenue) reached an adjusted EBITDA margin of 25.3%. Investing.com
- Strategic Portfolio Rationalization: Eurofins signed an agreement to divest its Electrical and Electronics Testing unit (MET Labs) to UL Solutions for an enterprise value of €575 million on a cash/debt-free basis, unlocking capital from a non-core testing line at an attractive valuation. Investing.com
- Site Ownership Strategy: Added 21,600 m² of owned high-throughput campus capacity while trimming leased footprints by 4,600 m², decreasing long-term lease liabilities.
Next Quarter/Semester Monitoring Focus:
- BioPharma Inflection Point: Monitoring whether delayed biopharma research budgets and early-stage CRO demand show an acceleration in H2 2026, as forecasted by management.
- Digital Transformation Milestones: Execution of proprietary laboratory information management system (LIMS) rollouts, targeted to complete by 2027 to lower ongoing administrative and IT operating expenditures.
- Closure of MET Labs Divestment: Final regulatory approvals and cash deployment plans (potential debt paydown or opportunistic share repurchases).
Future Outlook:
- Management reconfirmed progress toward its FY 2027 objective of achieving a 24% Adjusted EBITDA margin across the entire Group. Public Technologies (PUBT)
- Target net operating capex is projected at ~€400 million annually, supplemented by ~€200 million per year in owned campus development through 2027. Business Wire
- Leverage is targeted to stay within 1.5x–2.5x net debt-to-EBITDA.

Three-Month Share Price Performance (June – September 2026)

Eurofins Scientific (EPA: ERF) traded on Euronext Paris moved from €65.04 on June 4, 2026 to €71.56 as of September 1, 2026, representing an overall three-month gain of approximately +10.0%:

June 2026: The stock consolidated in the €62.50–€65.50 range, reflecting broader European equity volatility and general market skepticism surrounding prolonged weakness in early-phase life sciences research spending. Business Wire
Late July 2026 Earnings Reaction: The stock climbed into the €70.00 range ahead of earnings, followed by a brief post-earnings pullback to €66.12 on July 23 as investors evaluated slow organic top-line momentum (+2.7%) despite the strong margin expansion (+130 bps). Investing.com
August 2026 Rally: The share price mounted a steady recovery toward €73.30+, buoyed by investor recognition of strong free cash flow generation (€403 million), progress toward the 2027 24% margin target, accretive portfolio moves (MET Labs sale at €575 million), and active capital return through share repurchases. Public Technologies (PUBT)

Sources Investing.com

Back to Eurofins

Tagged eurofins